EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   2.7.8.27 | Acquired Immunodeficiency Syndrome |
16026301 |
Current status and perspectives in ceramide-targeting molecular medicine. |
diagnostic usage
unassigned |
3
0 |
| 2.7.8.27 | Alzheimer Disease |
16026301 |
Current status and perspectives in ceramide-targeting molecular medicine. |
diagnostic usage
unassigned |
3
0 |
| 2.7.8.27 | Alzheimer Disease |
30243987 |
Inhibition of sphingomyelin synthase 1 ameliorates alzheimer-like pathology in APP/PS1 transgenic mice through promoting lysosomal degradation of BACE1. |
causal interaction
unassigned |
1
0 |
| 2.7.8.27 | Asthma |
32072647 |
Ceramide/sphingosine-1-phosphate imbalance is associated with distinct inflammatory phenotypes of uncontrolled asthma. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
1
4
1
0 |
| 2.7.8.27 | Atherosclerosis |
16026301 |
Current status and perspectives in ceramide-targeting molecular medicine. |
diagnostic usage
unassigned |
3
0 |
| 2.7.8.27 | Atherosclerosis |
19590047 |
Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice. |
causal interaction
ongoing research
unassigned |
1
4
0 |
| 2.7.8.27 | Atherosclerosis |
20717634 |
[Sphingomyelin synthase 2 deficiency decreases atherosclerosis and inhibits inflammation in mice.] |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
3
4
2 |
| 2.7.8.27 | Atherosclerosis |
22538014 |
Sphingomyelin synthase 2 over-expression induces expression of aortic inflammatory biomarkers and decreases circulating EPCs in ApoE KO mice. |
causal interaction
ongoing research
unassigned |
1
4
0 |
| 2.7.8.27 | Atherosclerosis |
22580896 |
Impact of sphingomyelin synthase 1 deficiency on sphingolipid metabolism and atherosclerosis in mice. |
causal interaction
ongoing research
therapeutic application
unassigned |
2
4
1
0 |
| 2.7.8.27 | Atherosclerosis |
25032960 |
Pharmacologic inhibition of sphingomyelin synthase (SMS) activity reduces apolipoprotein-B secretion from hepatocytes and attenuates endotoxin-mediated macrophage inflammation. |
causal interaction
ongoing research
unassigned |
4
4
0 |
